Trifolirhizin reduces osteoclast formation and prevents inflammatory osteolysis by inhibiting RANKL‐induced activation of NF‐κB and MAPK signaling pathways and ROS

Abstract Inflammatory osteolysis is often caused by the excessive activation of osteoclasts stimulated by bacterial products such as lipopolysaccharide. The natural flavonoid trifolirhizin (TRI) has anti‐inflammatory properties; however, its function in inflammatory bone lysis remains unclear. This study aimed to elucidate the potential regulatory mechanisms of TRI in osteoclasts.Tartrate‐resistant acid phosphatase (TRAP) staining, acid secretion assays, podosomal actin belt fluorescence staining, and bone resorption assays were used to investigate the effects of TRI on osteoclast differentiation and bone resorption. A reactive oxygen species (ROS) measurement kit was used to detect the effect of TRI on ROS levels in osteoclasts. The effects of TRI on genes and signaling pathways related to osteoclast differentiation were determined by quantitative polymerase chain reaction (qPCR) and western blotting. A mouse model of lipopolysaccharide‐mediated inflammatory osteolysis was established, and the effects of TRI treatment on bone mass were observed using micro‐CT and histological examination. Mechanistically, TRI reduced ROS production by inhibiting receptor activator of nuclear factor‐κB ligand (RANKL)‐induced activation of the nuclear factor‐κB (NF‐κB) and mitogen‐activated protein kinase (MAPK) signaling pathways, and by upregulating the expression levels of the anti‐ROS enzymes heme oxygenase‐1 (HO‐1) and catalase (CAT), which contributed to the degradation of ROS, ultimately leading to a decrease in osteoclastogenesis. TRI inhibited osteoclast formation and ameliorated lipopolysaccharide (LPS)‐mediated inflammatory osteolysis. Thus, TRI may be a candidate agent for anti‐inflammatory osteolysis.